

## **Dr. Steven A. Hofstadler Receives 2004 PerkinElmer Life Sciences Award for Innovation in High-Throughput Affinity Screening**

September 1, 2004

DANBURY, Conn., Sept. 1 /PRNewswire/ -- Steven A. Hofstadler, Ph.D., Vice President of Ibis Therapeutics&reg;, a research program of Isis Pharmaceuticals, Inc., will be awarded the 2004 PerkinElmer Life Sciences Award. The presentation of this award will take place on Tuesday, September 14, during The Society for Biomolecular Screening 10th Anniversary Conference and Exhibition in Orlando, Florida, September 11-15, 2004. Dr. Hofstadler's award lecture is titled 'Multitarget Affinity/Specificity Screening (MASS): High- Throughput Affinity Screening (HTS) Using High Performance Mass Spectrometry (MS).'

The PerkinElmer Life Sciences Award for Innovation in HTS -- PerkinElmer Life Sciences sponsors an annual award of \$5,000 in recognition of a scientist's contribution to the advancement of high-throughput screening. The contribution may encompass development, innovation, and/or education in the areas of assay design, assay screening or automation.

Dr. Hofstadler has been a member of the Ibis Therapeutics team for the last seven years. He has been integral in the development of Ibis' unique biosensor technology called Triangulation Identification Genetic Evaluation of Risks or TIGER. The TIGER system can rapidly and simultaneously identify a broad range of infectious organisms. This system involves advanced MS instrumentation and methods, which Dr. Hofstadler has been responsible for developing. In addition, he oversees the primary high-throughput affinity screening activities of Ibis.

Dr. Hofstadler has coordinated MS efforts for several Defense Advanced Research Projects Agency (DARPA) programs: Drugs for Engineered Biological Warfare Bacteria, Universal Pathogen Protection, TIGER, and an on-going program with the Centers for Disease Control and Prevention: Automated Simultaneous Detection of Bioterrorism Agents.

Dr. Hofstadler received a Ph.D. in Analytical Chemistry from The University of Texas at Austin. Upon completing his graduate studies, he worked as a Post-Doctoral Research Fellow at Pacific Northwest National Laboratory in the laboratory of Richard Smith where he developed high performance instrumentation and methodologies based on Fourier transform ion cyclotron resonance (FTICR) mass spectrometry.

Upon completion of his post-doctoral studies, he remained at Pacific Northwest National Laboratory as a Senior Research Scientist for nearly five years where he continued to develop FTICR instrumentation in combination with numerous microcolumn separations. In 1997, Dr. Hofstadler joined Isis. His current research interests include applications of high performance MS for the analysis of nucleic acids as a means to characterize microorganisms, and the characterization of noncovalent complexes between RNA and small drug-like molecules.

Dr. Hofstadler has authored more than 95 scientific publications and holds six U.S. patents. He received R&D 100 Award in 2000 for "Multitarget Affinity/Specificity Screening." Dr. Hofstadler serves on the Scientific Advisory Board for Bruker Biosciences, the scientific committee for Laboratory Automation, the A-page Advisory Panel for American Chemical Society journal Analytical Chemistry, and the National Institutes of Health Special Emphasis Review Panel.

About Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) is exploiting its expertise in RNA to discover and develop novel human therapeutic drugs for its pipeline and for its partners. The company has successfully commercialized the world's first antisense drug and has 10 antisense products in development to treat metabolic, cardiovascular, inflammatory and viral diseases and cancer. Through its Ibis Therapeutics program, Isis is developing a biosensor to identify infectious organisms, and is discovering small molecule drugs that bind to RNA. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of more than 1,400 issued patents worldwide. Additional information about Isis is available at [www.isispharm.com](http://www.isispharm.com)

About The Society for Biomolecular Screening

The Society for Biomolecular Screening is the only non-profit international scientific Society dedicated to drug discovery and its related disciplines. It provides a forum for global education and information exchange among inter-disciplinary professionals in the chemical, pharmaceutical, biotech, and agrochemical industries. The SBS Endowment Fund Small Grants program annually presents \$25,000 to worthy recipients. Visit The Society for Biomolecular Screening web site -- [www.sbsonline.org](http://www.sbsonline.org)

For further information, contact Jim Toner (203) 743-1336 ext 111 ([jtoner@sbsonline.org](mailto:jtoner@sbsonline.org))

Ibis Therapeutics&reg; is a registered trademark of Isis Pharmaceuticals, Inc.

---

Source: Society for Biomolecular Screening